In addition, it was noted based on a meta-analysis of six trials of greater than 13,000 metformin-naïve T2D patients treated with either SGLT-2 inhibitors or GLP-1 RAs (3 trials with each class of drugs) that both groups of drugs reduced MACE [105]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.